Literature DB >> 27209303

Naringin and Sertraline Ameliorate Doxorubicin-Induced Behavioral Deficits Through Modulation of Serotonin Level and Mitochondrial Complexes Protection Pathway in Rat Hippocampus.

Mohit Kwatra1,2, Ashok Jangra3, Murli Mishra4, Yogita Sharma3, Sahabuddin Ahmed3, Pinaki Ghosh5, Vikas Kumar6, Divya Vohora6, Razia Khanam6,7.   

Abstract

The present study was designed to investigate the neuroprotective effect of naringin (NR) alone as well as its combination with sertraline (SRT) against doxorubicin (DOX)-induced neurobehavioral and neurochemical anomalies. DOX (15 mg/kg; i.p.) administration caused behavioral alterations, oxidative stress, neuroinflammation, mitochondrial dysfunction and monoamines alteration in male Wistar rats. NR (50 and 100 mg/kg; i.p.) and SRT (5 mg/kg; i.p.) treatment significantly attenuated DOX-induced anxiety and depressive-like behavior as evident from elevated plus maze (EPM) and modified forced swimming test (mFST), respectively. NR treatment significantly attenuated DOX-induced raised plasma corticosterone (CORT), tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β) levels in the hippocampus (HC). Furthermore, we found that combination of NR and SRT regimen ameliorated DOX-induced behavioral anomalies through modulation of the 5-HT level and mitochondrial complexes protection pathway along with alleviation of oxidative stress in the HC region. Therefore, NR treatment alone or in combination with SRT could be beneficial against DOX-induced neurotoxicity.

Entities:  

Keywords:  Doxorubicin; Mitochondrial complexes; Monoamines; Naringin; Oxidative stress; Sertraline

Mesh:

Substances:

Year:  2016        PMID: 27209303     DOI: 10.1007/s11064-016-1949-2

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  85 in total

Review 1.  Quality of life among long-term cancer survivors.

Authors:  B R Ferrell; K Hassey Dow
Journal:  Oncology (Williston Park)       Date:  1997-04       Impact factor: 2.990

Review 2.  Mitochondria and degenerative disorders.

Authors:  M Orth; A H Schapira
Journal:  Am J Med Genet       Date:  2001

Review 3.  The role of NAD(P)H oxidoreductase (DT-Diaphorase) in the bioactivation of quinone-containing antitumor agents: a review.

Authors:  P L Gutierrez
Journal:  Free Radic Biol Med       Date:  2000-08       Impact factor: 7.376

4.  Hesperidin and Silibinin Ameliorate Aluminum-Induced Neurotoxicity: Modulation of Antioxidants and Inflammatory Cytokines Level in Mice Hippocampus.

Authors:  Ashok Jangra; Prajapati Kasbe; Surya Narayan Pandey; Shubham Dwivedi; Satendra S Gurjar; Mohit Kwatra; Murli Mishra; Athira K Venu; Kunjbihari Sulakhiya; Ranadeep Gogoi; Nitul Sarma; Babul K Bezbaruah; Mangala Lahkar
Journal:  Biol Trace Elem Res       Date:  2015-05-28       Impact factor: 3.738

5.  Effects of naringin on hydrogen peroxide-induced cytotoxicity and apoptosis in P388 cells.

Authors:  Syu-Ichi Kanno; Ai Shouji; Keiko Asou; Masaaki Ishikawa
Journal:  J Pharmacol Sci       Date:  2003-06       Impact factor: 3.337

6.  Protective effect of naringin against ischemic reperfusion cerebral injury: possible neurobehavioral, biochemical and cellular alterations in rat brain.

Authors:  Vaibhav Gaur; Aditi Aggarwal; Anil Kumar
Journal:  Eur J Pharmacol       Date:  2009-07-03       Impact factor: 4.432

7.  Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity.

Authors:  V Goossens; J Grooten; K De Vos; W Fiers
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

8.  Sodium Phenylbutyrate and Edaravone Abrogate Chronic Restraint Stress-Induced Behavioral Deficits: Implication of Oxido-Nitrosative, Endoplasmic Reticulum Stress Cascade, and Neuroinflammation.

Authors:  Ashok Jangra; Chandra Shaker Sriram; Shubham Dwivedi; Satendra Singh Gurjar; Md Iftikar Hussain; Probodh Borah; Mangala Lahkar
Journal:  Cell Mol Neurobiol       Date:  2016-02-17       Impact factor: 5.046

Review 9.  Doxorubicin: the good, the bad and the ugly effect.

Authors:  Cristina Carvalho; Renato X Santos; Susana Cardoso; Sónia Correia; Paulo J Oliveira; Maria S Santos; Paula I Moreira
Journal:  Curr Med Chem       Date:  2009-09-01       Impact factor: 4.530

Review 10.  Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review).

Authors:  Marco van Vulpen; Henk B Kal; Martin J B Taphoorn; Sherif Y El-Sharouni
Journal:  Oncol Rep       Date:  2002 Jul-Aug       Impact factor: 3.906

View more
  12 in total

Review 1.  Chemobrain in Breast Cancer: Mechanisms, Clinical Manifestations, and Potential Interventions.

Authors:  Giovana R Onzi; Nathalia D'Agustini; Solange C Garcia; Silvia S Guterres; Paula R Pohlmann; Daniela D Rosa; Adriana R Pohlmann
Journal:  Drug Saf       Date:  2022-05-23       Impact factor: 5.606

2.  Naringin Confers Protection against Psychosocial Defeat Stress-Induced Neurobehavioral Deficits in Mice: Involvement of Glutamic Acid Decarboxylase Isoform-67, Oxido-Nitrergic Stress, and Neuroinflammatory Mechanisms.

Authors:  Olawumi M Oladapo; Benneth Ben-Azu; Abayomi Mayowa Ajayi; Osagie Emokpae; Aya-Ebi Okubo Eneni; Itivere Adrian Omogbiya; Ezekiel O Iwalewa
Journal:  J Mol Neurosci       Date:  2020-08-07       Impact factor: 3.444

3.  The triangle of death of neurons: Oxidative damage, mitochondrial dysfunction, and loss of choline-containing biomolecules in brains of mice treated with doxorubicin. Advanced insights into mechanisms of chemotherapy induced cognitive impairment ("chemobrain") involving TNF-α.

Authors:  Xiaojia Ren; Jeriel T R Keeney; Sumitra Miriyala; Teresa Noel; David K Powell; Luksana Chaiswing; Subbarao Bondada; Daret K St Clair; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2018-12-26       Impact factor: 7.376

4.  Naringin Exhibits Mas Receptor-Mediated Neuroprotection Against Amyloid Beta-Induced Cognitive Deficits and Mitochondrial Toxicity in Rat Brain.

Authors:  Vibhav Varshney; Debapriya Garabadu
Journal:  Neurotox Res       Date:  2021-02-03       Impact factor: 3.911

Review 5.  Four decades of chemotherapy-induced cognitive dysfunction: comprehensive review of clinical, animal and in vitro studies, and insights of key initiating events.

Authors:  Ana Dias-Carvalho; Mariana Ferreira; Rita Ferreira; Maria de Lourdes Bastos; Susana Isabel Sá; João Paulo Capela; Félix Carvalho; Vera Marisa Costa
Journal:  Arch Toxicol       Date:  2021-11-02       Impact factor: 5.153

Review 6.  Advances in the Preclinical Study of Some Flavonoids as Potential Antidepressant Agents.

Authors:  León Jesús German-Ponciano; Gilberto Uriel Rosas-Sánchez; Eduardo Rivadeneyra-Domínguez; Juan Francisco Rodríguez-Landa
Journal:  Scientifica (Cairo)       Date:  2018-02-01

Review 7.  Mechanisms of Neurotoxic Symptoms as a Result of Breast Cancer and Its Treatment: Considerations on the Contribution of Stress, Inflammation, and Cellular Bioenergetics.

Authors:  Tamara E Lacourt; Cobi J Heijnen
Journal:  Curr Breast Cancer Rep       Date:  2017-04-22

8.  Mangiferin ameliorates intracerebroventricular-quinolinic acid-induced cognitive deficits, oxidative stress, and neuroinflammation in Wistar rats.

Authors:  Mandeep Kumar Arora; Anglina Kisku; Ashok Jangra
Journal:  Indian J Pharmacol       Date:  2020 Jul-Aug       Impact factor: 1.200

Review 9.  Doxorubicin-Induced Cognitive Impairment: The Mechanistic Insights.

Authors:  Jiajia Du; Aoxue Zhang; Jing Li; Xin Liu; Shuai Wu; Bin Wang; Yanhong Wang; Hongyan Jia
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

10.  Citrus Flavonoids as Promising Phytochemicals Targeting Diabetes and Related Complications: A Systematic Review of In Vitro and In Vivo Studies.

Authors:  Gopalsamy Rajiv Gandhi; Alan Bruno Silva Vasconcelos; Ding-Tao Wu; Hua-Bin Li; Poovathumkal James Antony; Hang Li; Fang Geng; Ricardo Queiroz Gurgel; Narendra Narain; Ren-You Gan
Journal:  Nutrients       Date:  2020-09-23       Impact factor: 6.706

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.